Cargando…
Improving Response Inhibition in Parkinson’s Disease with Atomoxetine
BACKGROUND: Dopaminergic drugs remain the mainstay of Parkinson’s disease therapy but often fail to improve cognitive problems such as impulsivity. This may be due to the loss of other neurotransmitters, including noradrenaline, which is linked to impulsivity and response inhibition. We therefore ex...
Autores principales: | Ye, Zheng, Altena, Ellemarije, Nombela, Cristina, Housden, Charlotte R., Maxwell, Helen, Rittman, Timothy, Huddleston, Chelan, Rae, Charlotte L., Regenthal, Ralf, Sahakian, Barbara J., Barker, Roger A., Robbins, Trevor W., Rowe, James B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384955/ https://www.ncbi.nlm.nih.gov/pubmed/24655598 http://dx.doi.org/10.1016/j.biopsych.2014.01.024 |
Ejemplares similares
-
Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease
por: Ye, Zheng, et al.
Publicado: (2014) -
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures
por: Ye, Zheng, et al.
Publicado: (2016) -
Targeting impulsivity in Parkinson’s disease using atomoxetine
por: Kehagia, Angie A., et al.
Publicado: (2014) -
Atomoxetine restores the response inhibition network in Parkinson’s disease
por: Rae, Charlotte L., et al.
Publicado: (2016) -
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease
por: Borchert, Robin J, et al.
Publicado: (2016)